ProfileGDS4814 / ILMN_1680231
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 17% 41% 31% 42% 27% 16% 24% 8% 29% 18% 32% 52% 16% 37% 26% 46% 27% 45% 14% 42% 22% 12% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)42.856817
GSM780708Untreated after 4 days (C2_1)47.935541
GSM780709Untreated after 4 days (C3_1)45.77631
GSM780719Untreated after 4 days (C1_2)48.143942
GSM780720Untreated after 4 days (C2_2)45.056227
GSM780721Untreated after 4 days (C3_2)42.718216
GSM780710Trastuzumab treated after 4 days (T1_1)44.45724
GSM780711Trastuzumab treated after 4 days (T2_1)40.70438
GSM780712Trastuzumab treated after 4 days (T3_1)45.369729
GSM780722Trastuzumab treated after 4 days (T1_2)43.01718
GSM780723Trastuzumab treated after 4 days (T2_2)45.89332
GSM780724Trastuzumab treated after 4 days (T3_2)51.334752
GSM780713Pertuzumab treated after 4 days (P1_1)42.672716
GSM780714Pertuzumab treated after 4 days (P2_1)47.04537
GSM780715Pertuzumab treated after 4 days (P3_1)44.725626
GSM780725Pertuzumab treated after 4 days (P1_2)49.328346
GSM780726Pertuzumab treated after 4 days (P2_2)45.016327
GSM780727Pertuzumab treated after 4 days (P3_2)48.95245
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)42.108414
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)48.210542
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)44.049722
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)41.759912
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)48.031941